Anyone interested in the current doings of the antibiotics antitrust litigation in the spring of 1975l could easily have found seating in the public section of the courtroom of Judge Miles A. Lord in Minneapolis. An instantly striking aspect of the courtroom was that, in contrast to the scattering of young attorneys and an occasional curious onlooker in the public section, there were dozens of people crowded into the area around the central raised bench on which Judge Lord sits. Several attorneys represenr: the defendants-five of the major drug manufacturing companies in the United States. Numerous counsel for the plaintiffs were grouped around a large table to Judge Lord's right. Clerks, court reporters, and marshals sat beneath the bench. The most remarkable feature of the crowd, however, was the presence of two jury boxes containing two separate juries. In fact, two different trials in six different cases were proceeding at once. “Jury One” was hearing evidence in actions brought by the United States, two national classes (one of insurance companies and the other of union health and welfare funds), and a California medical group. “Jury TWQ” was hearing evidence in suits brought in behalf of competitors of the defendant drug companies. For the most part, the juries were hearing evidence common to both sets of cases. When evidence was introduced that was relevant to only one set of cases, the other jvry would be excused.